Carfilzomib in the treatment of relapsed multiple myeloma – results of ASPIRE trial

03/2018

MUDr. Jan Straub

I. interní klinika - klinika hematologie 1. LF UK a VFN, Praha

SUMMARY

In the Czech Republic bortezomib and lenalidomide-based regimens (VD, CVD, VTD, RD) are the most commonly used second- and third-line therapies for patients with multiple myeloma (MM). Now is new combination - carfilzomib-lenalidomid-dexamethason (KRd) approved for the treatment for patients with relapse of MM. The approvals for the combination KRd were based on results of randomized ASPIRE trial, phase 3, which evaluated KRd versus Rd in patients with relapsed or refractory MM (1-3 previous lines of therapy). Treatment with KRd led to a significant reduction in the risk of disease progression or death. Progression-free survival was significantly improved with carfilzomib (median 26.3 months for KRd versus 17.6 months for Rd). Median overall survival was 48.3 months for KRd versus 40.4 months for Rd. Selected grade > 3 adverse events of interest included cardiac failure (4.3 % vs 2.1 %), ischemic heart disease (3.8 % vs 2.3 %) and arterial hypertension (6.4 % vs 2.3 %).

KEY WORDS

multiple myeloma, carfilzomib, treatment, KRd, ASPIRE trial